Big pharma
The largest drugmakers, selling prescription medicines worldwide.
Agrupadas con ayuda de un modelo de IA y revisadas por nuestros editores. La línea bajo cada empresa explica por qué está aquí.
Los precios de las acciones son el cierre del 11 nov 2026, del feed de la bolsa IEX.
Grade mix
A 7B 3C 3
Revenue growing
12 of 12
Free cash flow growing
9 of 13
Median price move, 1 year
+34,0 %
- LLYELI LILLY AND COMPANY
Drug manufacturers generalMarket cap 1,35T US$P/E 46,67
1437,79 US$+42,2 %1YSince added +23,2 %
A+- Crecimiento y caja
- Creciendo con fuerza
- Business trend
- Estable
- Business quality
- Fuerte
- Getting better
- Mejorando
Revenue
86,5B US$+45,5 %Profit
27,6B US$+49,8 %Free cash flow
19,7B US$+112,1 %Why it is here: Sells prescription medicines for diabetes, obesity, cancer and inflammation
- JNJJohnson & Johnson
Drug manufacturers generalMarket cap 674,9B US$P/E 42,54
280,34 US$+47,5 %1YSince added +12,8 %
A+- Crecimiento y caja
- Creciendo con fuerza
- Business trend
- Estable
- Business quality
- Fuerte
- Getting better
- Mixto
Revenue
99,3B US$+7,8 %Profit
16,1B US$-35,9 %Free cash flow
20,6B US$+5,1 %Why it is here: Sells prescription medicines for cancer and immune disorders
- ABBVAbbVie Inc.
Drug manufacturers generalMarket cap 521,2B US$P/E 50,75
294,87 US$+30,2 %1YSince added +7,5 %
B+- Crecimiento y caja
- Creciendo con fuerza
- Business trend
- Estable
- Business quality
- Fuerte
- Getting better
- Mejorando
Revenue
66B US$+10,7 %Profit
10,3B US$+333,1 %Free cash flow
18,9B US$-4,1 %Why it is here: Sells medicines for immune, neurological and cancer conditions
- MRKMerck & Co., Inc.
Drug manufacturers generalMarket cap 362,9B US$P/E 150,20
147,20 US$+65,7 %1YSince added +3,7 %
A- Crecimiento y caja
- Creciendo con fuerza
- Business trend
- Estable
- Business quality
- Sólida
- Getting better
- Mixto
Revenue
67,4B US$+4,9 %Profit
2,5B US$-87,1 %Free cash flow
14,7B US$+13,0 %Why it is here: Sells prescription medicines and vaccines for people and animals
- NVSNovartis AG
Drug manufacturers generalMarket cap 306B US$Sin PER (pérdida operativa)
160,36 US$+23,6 %1YSince added +12,6 %
A- Crecimiento y caja
- Creciendo con fuerza
- Business quality
- Mixta
- Getting better
- Mejorando con fuerza
Revenue
56,7B US$+9,6 %Profit
-46M US$No comparable yearFree cash flow
17,6B US$+8,3 %Why it is here: Sells prescription medicines
- AZNASTRAZENECA PLC
Drug manufacturers generalMarket cap 289,7B US$P/E 28,36
185,49 US$+115,2 %1YSince added +19,0 %
B+- Crecimiento y caja
- Creciendo con fuerza
- Business trend
- Desacelerando
- Business quality
- Fuerte
- Getting better
- Mejorando con fuerza
Revenue
62,4B US$+7,3 %Profit
10,2B US$+45,3 %Free cash flow
11,8B US$+18,4 %Why it is here: Sells prescription medicines
- NVONOVO NORDISK A/S
Drug manufacturers generalMarket cap 182,8B US$P/E 11,84
41,10 US$-15,4 %1YSince added +8,0 %
C+- Crecimiento y caja
- Creciendo
- Business trend
- Acelerando
- Business quality
- Fuerte
- Getting better
- Mejorando
Revenue
50,3B US$+5,7 %Profit
17,1B US$+9,1 %Free cash flow
8,9B US$-20,1 %Why it is here: Sells diabetes and obesity medicines
- PFEPFIZER INC
Drug manufacturers generalMarket cap 167,9B US$P/E 42,07
29,45 US$+21,4 %1YSince added +3,8 %
C- Crecimiento y caja
- Creciendo con fuerza
- Business trend
- Contrayéndose
- Business quality
- Sólida
- Getting better
- Mixto
Revenue
63,6B US$+1,3 %Profit
4B US$-59,0 %Free cash flow
11,8B US$+13,6 %Why it is here: Sells prescription medicines and vaccines
- BMYBRISTOL-MYERS SQUIBB COMPANY
Drug manufacturers generalMarket cap 128,6B US$P/E 13,95
62,92 US$+34,0 %1YSince added +11,0 %
C+- Crecimiento y caja
- Creciendo
- Business trend
- Estable
- Business quality
- Fuerte
- Getting better
- Mejorando con fuerza
Revenue
50B US$+4,2 %Profit
9,2B US$+53,1 %Free cash flow
9,3B US$-39,3 %Why it is here: Sells prescription medicines for cancer and immune conditions
- SNYSanofi
Drug manufacturers generalMarket cap 59,1B US$P/E 6,81
48,43 US$-3,0 %1YSince added +23,9 %
B- Crecimiento y caja
- Creciendo con fuerza
- Business trend
- Estable
- Business quality
- Mixta
- Getting better
- Mejorando
Revenue
53,5B US$+11,6 %Profit
4,7B US$-54,2 %Free cash flow
8,1B US$+22,5 %Why it is here: Sells prescription medicines and vaccines
- GSKGSK plc
Drug manufacturers generalMarket cap 109,2B US$P/E 13,60
50,60 US$+8,9 %1YSince added +9,3 %
A+- Crecimiento y caja
- Creciendo con fuerza
- Business quality
- Fuerte
- Getting better
- Mejorando con fuerza
Revenue
43,8B US$+4,1 %Profit
7,7B US$+122,0 %Free cash flow
8,6B US$+24,0 %Why it is here: Sells prescription medicines and vaccines worldwide
- AMGNAmgen Inc.
Drug manufacturers generalMarket cap 253,2B US$P/E 27,14
468,13 US$+43,1 %1YSince added +13,4 %
A+- Crecimiento y caja
- Creciendo con fuerza
- Business trend
- Estable
- Business quality
- Fuerte
- Getting better
- Mejorando
Revenue
38,9B US$+8,2 %Profit
9,4B US$+34,1 %Free cash flow
9,6B US$-17,0 %Why it is here: Develops and sells medicines and biosimilars for serious diseases
- TAKTakeda Pharmaceutical Company Limited
Drug manufacturers specialty and genericMarket cap 33,5B US$P/E 48,79
20,86 US$+50,1 %1YSince added +12,5 %
A- Crecimiento y caja
- Creciendo con fuerza
- Business quality
- Mixta
- Getting better
- Mixto
Revenue
29,8B US$No comparable yearProfit
259,4M US$No comparable yearFree cash flow
5,5B US$+1,1 %Why it is here: Sells prescription medicines and vaccines globally
Green and red compare each figure with the same window a year earlier. Grades and checks are the company page's own; nothing here is a recommendation.
Lists are their owners' own, and notes and comments are opinions. Grades describe businesses from their filings; nothing here is a recommendation to buy or sell.
DiscussionNo comments yet
Be civil and stick to the companies. Comments are opinions, not advice.